YourChoice Therapeutics GTM brain

YourChoice Therapeutics is developing an investigational non-hormonal oral contraceptive for men.

category

Investigational male contraception

market profile

  • text: Men's established contraceptive choices remain condoms and vasectomy; novel drugs and devices are in clinical development.
  • text: YCT-529 is in Phase 1b/2a research, not an approved or commercially available contraceptive.
  • text: A first-in-human study examined safety, tolerability and pharmacokinetics, rather than establishing contraceptive efficacy.

personas

  • title: Potential male trial participant
    pains:
    • Wants greater responsibility for contraception without limiting options to condoms or vasectomy
    • Needs a clear explanation of eligibility, uncertainty and time commitments before joining a clinical study
  • title: Clinical research site investigator
    pains:
    • Must recruit protocol-eligible participants and monitor safety over repeat doses
    • Needs reliable data and evidence before assessing a new mechanism
  • title: Life sciences investor or development partner
    pains:
    • Must assess clinical and regulatory uncertainty before backing an unapproved drug
    • Needs a credible evidence path from small early studies to larger efficacy trials

icp

  • text: Clinical study sites serving healthy men who satisfy the current protocol, including certain men planning vasectomy or not planning future children; eligibility is determined by investigators.
  • text: Potential institutional partners include reproductive health research organizations, clinical development partners and life sciences investors; no company size criterion is established.

message pillars

  • text: Expand the number of contraceptive choices available to men.
  • text: Study a daily, non-hormonal oral approach.
  • text: Communicate the evidence boundaries clearly.

objections

  • objection: Is the pill proven safe and effective?
    response: It is investigational, and the company explicitly says safety and efficacy for any use are not established.
  • objection: Does stopping the drug restore fertility?
    response: The company describes reversal in preclinical studies; human reversibility is not established by that finding.

competitors

  • name: Contraline
    website: https://www.contraline.com/trials
    why: Developing ADAM, an investigational non-hormonal male contraceptive implant, as a different potential method.
  • name: NEXT Life Sciences
    why: Developing Vasalgel, another investigational male contraceptive approach described in a clinical review.

influencers

  • name: Heather Vahdat
    url: https://www.statnews.com/2026/02/02/male-birth-control-clinical-trial-volunteers-men-want-this/
    why: Male Contraceptive Initiative executive director and public advocate for male contraceptive research.

keywords

  • male birth control pill
  • non hormonal male contraception
  • YCT-529 clinical trial
  • male contraceptive research
  • male birth control study
  • male contraceptive alternatives

voice

  • Scientific and accessible
  • Careful about investigational status
  • Choice-oriented

signals

  • text: A research site conducts reproductive health trials and can recruit men matching the relevant study protocol.
  • text: An investor or organization funds early-stage male contraception or reproductive health research.

pricing

model: unknown

motion

unknown

channels

  • scientific publications
  • clinical trial registries
  • press
  • scientific meetings

confidence

medium

Founders

  • name: Akash Bakshi
    title: Founder
    role: Founder
  • name: Nadja Mannowetz
    title: Founder
    role: Founder

Back to YC companies